Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) reported Q1 2026 results and provided clinical updates. Q1 net product revenue was $20.0M; net loss was $33.0M ($0.21/share) and adjusted net loss was $19.7M ($0.13/share). Cash and cash equivalents totaled $231.0M with a runway at least into 2028. Key clinical catalysts: LOTIS-5 topline expected in 2Q 2026 and full LOTIS-5 and LOTIS-7 data anticipated by year-end.
ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 49,400 common shares to two new employees on May 1, 2026 as material inducements under its Inducement Plan.
The Compensation Committee approved the grants, made under the NYSE employment inducement exemption (Rule 303A.08). Vesting is 25% at the first anniversary, then 1/48th monthly thereafter, with full vesting at the fourth anniversary subject to continued employment.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, May 4, 2026 at 8:30 a.m. EDT to report first-quarter 2026 financial results and provide operational updates. Participants are asked to register; a North America toll-free dial-in is provided and the webcast will be archived for 30 days.
ADC Therapeutics (NYSE: ADCT) granted an inducement equity award of 17,000 options to a new employee on April 1, 2026. The award was approved by the Compensation Committee under the company's Inducement Plan and relies on the NYSE employment inducement exemption Rule 303A.08.
The options vest 25% after one year and then 1/48th monthly, fully vesting after four years, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported fourth quarter and full year 2025 results and provided clinical and financing updates. Key highlights include LOTIS-5 Phase 3 topline expected 2Q 2026, full LOTIS-5 and LOTIS-7 data by year-end 2026, $261.3M cash as of Dec 31, 2025, and amended royalty financing with warrants.
Fourth quarter product revenue was $22.3M and full year product revenue was $73.6M; full year net loss was $142.6M. Company expects cash runway at least into 2028.
ADC Therapeutics (NYSE: ADCT) will report fourth quarter and full year 2025 results on March 10, 2026 via a conference call and live webcast at 8:30 a.m. EDT. The call will include financial results for the period ended December 31, 2025, and operational updates.
Investors may register in advance; a participant toll-free dial-in for North America and Canada is provided and the webcast archive will be available for 30 days.
ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 135,000 common shares to three new employees on March 2, 2026 as inducements for employment. The Compensation Committee approved the awards under the company's Inducement Plan relying on the NYSE employment inducement exemption.
The awards vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) will participate in investor conferences in March 2026, including TD Cowen 46th Annual Health Care Conference and Jefferies Biotech on the Beach Summit. Presentations include a corporate presentation by CEO Ameet Mallik on March 3, 2026 in Boston and one-on-one meetings on March 11, 2026 in Miami.
A webcast of the March 3 presentation will be available on the company’s Investors Events & Presentations page with a replay accessible for about 30 days.
ADC Therapeutics (NYSE: ADCT) amended its royalty purchase agreement with HealthCare Royalty to increase strategic flexibility for ZYNLONTA®. Key changes: the change-of-control payment is reduced to $150M through Dec 31, 2027 and $200M thereafter; HealthCare Royalty received warrants for ~9.8M common shares at $3.81 exercisable through Dec 31, 2030. Royalties continue to be payable to an acquirer until the original royalty cap, and buyout options of $525M (pre-2029 deadline) or $750M (post-2029) remain in place.
ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 308,000 common shares to seven new employees on February 2, 2026 under its Inducement Plan.
The awards vest 25% after one year and then monthly over three years, relying on the NYSE employment inducement exemption.